HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Engler, D. A. Articles by Niyogi, S. K. Search for Related Content PubMed PubMed Citation Articles by Engler, D. A. Articles by Niyogi, S. K. Social Bookmarking                      What's this?

J. Biol. Chem., Vol. 267, Issue 4, 2274-2281, Feb, 1992

Critical functional requirement for the guanidinium group of the arginine 41 side chain of human epidermal growth factor as revealed by mutagenic inactivation and chemical reactivation

DA Engler, SR Campion, MR Hauser, JS Cook and SK Niyogi
Protein Engineering and Molecular Mutagenesis Program, Oak Ridge National Laboratory, Tennessee 37831-8077.

In a preliminary study we demonstrated that the formation of the epidermal growth factor (EGF) receptor-ligand complex requires the participation of the highly conserved arginine 41 side chain of the growth factor peptide (Engler, D.A., Montelione, G.T., and Niyogi, S.K. (1990) FEBS Lett. 271, 47-50). In an attempt to gain further insight into the nature of this interaction(s), we used both site-directed mutagenesis and chemical modification reagents to produce human EGF (hEGF) analogues with altered chemical properties of the residue 41 side chain. Eight mutant analogues of hEGF were generated, substituting arginine 41 with lysine, glutamine, isoleucine, tyrosine, glycine, alanine, aspartate, or glutamate. Although each of the mutant analogues was able to displace wild-type hEGF fully in receptor competition binding assays, affinity of the receptor for the mutants was substantially reduced, varying from 0.4 to less than 0.01% of that observed for wild-type growth factor. At sufficiently high concentrations these mutants were able to stimulate DNA synthesis in mouse keratinocytes. Substitution of lysine for arginine 41 reduced the receptor affinity 250-fold from that observed for wild type, despite retention of the positive electrostatic charge. The lysine substitution leaves a reactive amine at position 41 and made it possible, using amine-specific chemical modification reagents, to produce selected arginine homologues that were tested for their effects on receptor binding, receptor tyrosine kinase activation, and stimulation of DNA synthesis in mouse keratinocytes. The reaction of lysine 41 with methyl acetimidate resulted in a lysineacetamidine product which only partially restored activity of the lysine hEGF mutant. However, reaction with O-methylisourea resulted in generation of an arginine 41 homologue (homoarginine) which restored full activity. The results indicate that the chemical properties inherent in the guanidinium group of the arginine 41 side chain of hEGF are responsible for optimal receptor-ligand association.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. Biswas, S. Lewis, B. Wang, M. Miyagi, P. Santoshkumar, M. H. Gangadhariah, and R. H. Nagaraj Chemical Modulation of the Chaperone Function of Human {alpha}A-Crystallin J. Biochem., July 1, 2008; 144(1): 21 - 32. [Abstract] [Full Text] [PDF]

				J. R. Cochran, Y.-S. Kim, S. M. Lippow, B. Rao, and K.D. Wittrup Improved mutants from directed evolution are biased to orthologous substitutions Protein Eng. Des. Sel., June 1, 2006; 19(6): 245 - 253. [Abstract] [Full Text] [PDF]

				M. Bach, P. Holig, E. Schlosser, T. Volkel, A. Graser, R. Muller, and R. E. Kontermann Isolation from phage display libraries of lysine-deficient human epidermal growth factor variants for directional conjugation as targeting ligands Protein Eng. Des. Sel., December 1, 2003; 16(12): 1107 - 1113. [Abstract] [Full Text] [PDF]

				R. A. Vacca, S. Giannattasio, R. Graber, E. Sandmeier, E. Marra, and P. Christen Active-site Arg right-arrow Lys Substitutions Alter Reaction and Substrate Specificity of Aspartate Aminotransferase J. Biol. Chem., August 29, 1997; 272(35): 21932 - 21937. [Abstract] [Full Text] [PDF]

				SarahM. Puddicombe, L. Wood, StephenG. Chamberlin, and DonnaE. Davies The Interaction of an Epidermal Growth Factor/Transforming Growth Factor alpha Tail Chimera with the Human Epidermal Growth Factor Receptor Reveals Unexpected Complexities J. Biol. Chem., November 29, 1996; 271(48): 30392 - 30397. [Abstract] [Full Text] [PDF]

				S. G. Chamberlin, K. J. Sargood, A. Richter, J. M. Mellor, D. W. Anderson, N. G. J. Richards, D. L. Turner, R. P. Sharma, P. Alexander, and D. E. Davies Constrained Peptide Analogues of Transforming Growth Factor-alpha Residues Cysteine 21-32 Are Mitogenically Active J. Biol. Chem., September 8, 1995; 270(36): 21062 - 21067. [Abstract] [Full Text] [PDF]

				E. G. Barbacci, B. C. Guarino, J. G. Stroh, D. H. Singleton, K. J. Rosnack, J. D. Moyer, and G. C. Andrews The Structural Basis for the Specificity of Epidermal Growth Factor and Heregulin Binding J. Biol. Chem., April 21, 1995; 270(16): 9585 - 9589. [Abstract] [Full Text] [PDF]

				T. Itoh, M. Kondo, Y. Tanaka, M. Kobayashi, R. Sasada, K. Igarashi, M. Suenaga, N. Koyama, O. Nishimura, and M. Fujino Novel Betacellulin Derivatives. SEPARATION OF THE DIFFERENTIATION ACTIVITY FROM THE MITOGENIC ACTIVITY J. Biol. Chem., October 26, 2001; 276(44): 40698 - 40703. [Abstract] [Full Text] [PDF]